Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance

被引:31
作者
Boswell, FJ [1 ]
Andrews, JM [1 ]
Jevons, G [1 ]
Wise, R [1 ]
机构
[1] City Hosp NHS Trust, Dept Microbiol, Birmingham B18 7QH, W Midlands, England
关键词
D O I
10.1093/jac/dkf152
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In this study the in vitro activities and pharmacodynamic properties of moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin were compared on recently isolated respiratory pathogens and strains of Streptococcus pneumoniae with known mechanisms of fluoroquinolone resistance. In addition, the resistance selection frequencies of moxifloxacin and levofloxacin on three recently isolated respiratory pathogens and four strains of S. pneumoniae with known mechanisms of fluoroquinolone resistance were investigated. The four fluoroquinolones had similar activities against both Moraxella catarrhalis (MIC(90)s 0.015-0.06 mg/L) and Haemophilus influenzae (MIC(90)s 0.008-0.03 mg/L). More marked differences in activity were noted with S. pneumoniae, with MIC(90)s of 0.25, 1, 0.5 and 0.03 mg/L for moxifloxacin, levofloxacin, gatifloxacin and gemifloxacin, respectively. With the S. pneumoniae strains, the four fluoroquinolones exhibited similar concentration-dependent time-kill kinetics. The resistance selection frequencies of levofloxacin were higher than those of moxifloxacin at concentrations equivalent to those at the end of the dosing interval. Therefore moxifloxacin may have less of an impact on the development of resistance than levofloxacin.
引用
收藏
页码:495 / 502
页数:8
相关论文
共 26 条
[21]   Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy [J].
Soman, A ;
Honeybourne, D ;
Andrews, J ;
Jevons, G ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :835-838
[22]   Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? [J].
Thomson, KS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (06) :719-723
[23]   The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones [J].
Wise, R ;
Brenwald, NP ;
Andrews, JM ;
Boswell, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (04) :447-452
[24]   The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone [J].
Wise, R ;
Andrews, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :679-688
[25]   In vitro activity of BAY 12-8039, a new fluoroquinolone [J].
Woodcock, JM ;
Andrews, JM ;
Boswell, FJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :101-106
[26]   Application of fluoroquinolone pharmacodynamics [J].
Wright, DH ;
Brown, GH ;
Peterson, ML ;
Rotschafer, JC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) :669-683